Dr Mohty on the Potential Role of BCMA-Targeted Bispecific Antibodies in Myeloma

Mohamad Mohty, MD, PhD, professor, hematology, Sorbonne University, head, Clinical Hematology and Cellular Therapy Department, Saint-Antoine Hospital discusses the potential role of treatment with BCMA-targeted bispecific antibodies in the treatment of multiple myeloma.

There have been significant strides made in the treatment armamentarium for patients with relapsed/refractory multiple myeloma, Mohty begins, specifically for those patients who may be triple-exposed or triple-refractory.

Currently, Mohty notes that BCMA-targeted bispecific antibodies are primarily utilized in the treatment of patients with advanced relapsed or refractory disease. These targeted approaches have shown efficacy in this setting, offering a new therapeutic option for patients who have exhausted other treatments. Future research aveneus will focus on moving these bispecific antibodies into earlier lines of therapy, aiming to further enhance patient outcomes in the long run, Mohty explains.

Besides integrating BCMA targeted therapies into earlier lines of treatment, Mohty mentions another area of exploration which will assess the combination of bispecific antibodies with other therapeutic modalities.

Mohty says that possible approaches may include pairing bispecific antibodies with immunomodulatory drugs, anti-CD38 monoclonal antibodies, or even with other bispecific antibodies targeting different antigens. These combinations are anticipated to enhance therapeutic efficacy by leveraging multiple mechanisms of action, potentially leading to deeper and more durable responses in patients with multiple myeloma. The development of these novel combinations is expected to be a key focus of research over the next 5-10 years, Mohty emphasizes.

The future use of BCMA-targeted bispecific antibodies in multiple myeloma appears promising, particularly as these agents are integrated into earlier treatment lines and combined with other therapies, he notes. Ongoing research is necessary to determine the most effective strategies for incorporating these innovative treatments into clinical practice, with the goal of achieving better outcomes for patients with myeloma, Mohty concludes.